[4P-0549(1PW-13-8)] Molecular mechanism and potential target indication of TAK-931, a novel CDC7-selective inhibitor
Kenichi Iwai1,2,7, Tadahiro Nambu1, Ryo Dairiki1, Momoko Ohori1, JIe Yu2, Krissy Burke2, Masamitsu Gotou3, Yukiko Yamamoto1, Shunsuke Ebara1, Sachio Shibata1, Ryosuke Hibino1, Satoru Nishizawa1, Tohru Miyazaki1, Misaki Homma1, Yuya Oguro1, Takashi Imada1, Nobuo Cho1, Noriko Uchiyama4, Akifumi Kogame5, Toshiyuki Takeuchi5, Osamu Kurasawa1, Kazunori Yamanaka3, Huifeng Niu6, 〇Akihiro Ohashi1,2,7
(1.Onc. DDU, Takeda Pharmaceutical Company Limited, 2.Onc. DDU, Takeda Pharmaceuticals International Co., 3.InteRL Lab., Takeda Pharmaceutical Company Limited, 4.Biomol. Res. Lab., Takeda Pharmaceutical Company Limited, 5.DMPK Res. Lab., Takeda Pharmaceutical Company Limited, 6.Translational & Biomarker Res., Takeda Pharmaceuticals International Co., 7.Div. Translational Genomics, EPOC, National Cancer Center)
CDC7 inhibitor, TAK-931, replication stress, cancer therapeutic drug, predictive biomarker